194 related articles for article (PubMed ID: 30173322)
21. DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations.
Gaudet MM; Campan M; Figueroa JD; Yang XR; Lissowska J; Peplonska B; Brinton LA; Rimm DL; Laird PW; Garcia-Closas M; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3036-43. PubMed ID: 19861523
[TBL] [Abstract][Full Text] [Related]
22. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic Alteration by DNA Methylation of ESR1, MYOD1 and hTERT Gene Promoters is Useful for Prediction of Response in Patients of Locally Advanced Invasive Cervical Carcinoma Treated by Chemoradiation.
Sood S; Patel FD; Ghosh S; Arora A; Dhaliwal LK; Srinivasan R
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):720-7. PubMed ID: 26344356
[TBL] [Abstract][Full Text] [Related]
24. Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors.
Yoshida T; Eguchi H; Nakachi K; Tanimoto K; Higashi Y; Suemasu K; Iino Y; Morishita Y; Hayashi S
Carcinogenesis; 2000 Dec; 21(12):2193-201. PubMed ID: 11133808
[TBL] [Abstract][Full Text] [Related]
25. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
26. ESR1 promoter methylation in squamous cell cervical cancer.
Kirn V; Zaharieva I; Heublein S; Thangarajah F; Friese K; Mayr D; Jeschke U
Anticancer Res; 2014 Feb; 34(2):723-7. PubMed ID: 24511005
[TBL] [Abstract][Full Text] [Related]
27. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.
Widschwendter M; Siegmund KD; Müller HM; Fiegl H; Marth C; Müller-Holzner E; Jones PA; Laird PW
Cancer Res; 2004 Jun; 64(11):3807-13. PubMed ID: 15172987
[TBL] [Abstract][Full Text] [Related]
28. The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women.
Prabhu JS; Wahi K; Korlimarla A; Correa M; Manjunath S; Raman N; Srinath BS; Sridhar TS
Tumour Biol; 2012 Apr; 33(2):315-23. PubMed ID: 22362381
[TBL] [Abstract][Full Text] [Related]
29. DNA Methylation Status of the Estrogen Receptor α Gene in Canine Mammary Tumors.
Brandão YO; Toledo MB; Chequin A; Cristo TG; Sousa RS; Ramos EAS; Klassen G
Vet Pathol; 2018 Jul; 55(4):510-516. PubMed ID: 29566609
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
31. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.
Franken A; Honisch E; Reinhardt F; Meier-Stiegen F; Yang L; Jaschinski S; Esposito I; Alberter B; Polzer B; Huebner H; Fasching PA; Pancholi S; Martin LA; Ruckhaeberle E; Schochter F; Tzschaschel M; Hartkopf AD; Mueller V; Niederacher D; Fehm T; Neubauer H
J Mol Diagn; 2020 Jan; 22(1):111-121. PubMed ID: 31669227
[TBL] [Abstract][Full Text] [Related]
32. [Correlation between the methylation status of Runx3 gene and positive expression of estrogen receptor in breast cancer].
Yan Z; Gao S; Wu X; Liu H
Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):240-4. PubMed ID: 25975905
[TBL] [Abstract][Full Text] [Related]
33. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.
Stone A; Zotenko E; Locke WJ; Korbie D; Millar EK; Pidsley R; Stirzaker C; Graham P; Trau M; Musgrove EA; Nicholson RI; Gee JM; Clark SJ
Nat Commun; 2015 Jul; 6():7758. PubMed ID: 26169690
[TBL] [Abstract][Full Text] [Related]
34. ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.
Angus L; Beije N; Jager A; Martens JW; Sleijfer S
Cancer Treat Rev; 2017 Jan; 52():33-40. PubMed ID: 27886589
[TBL] [Abstract][Full Text] [Related]
35. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
[TBL] [Abstract][Full Text] [Related]
36. Differential DNA methylation and CTCF binding between the ESR1 promoter a of MCF-7 and MDA-MB-231 breast cancer cells.
Montes-de-Oca-Fuentes EV; Jácome-López K; Zarco-Mendoza A; Guerrero G; Ventura-Gallegos JL; Juárez-Méndez S; Cabrera-Quintero AJ; Recillas-Targa F; Zentella-Dehesa A
Mol Biol Rep; 2024 Jan; 51(1):148. PubMed ID: 38236307
[TBL] [Abstract][Full Text] [Related]
37. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
[TBL] [Abstract][Full Text] [Related]
38. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Clatot F; Perdrix A; Augusto L; Beaussire L; Delacour J; Calbrix C; Sefrioui D; Viailly PJ; Bubenheim M; Moldovan C; Alexandru C; Tennevet I; Rigal O; Guillemet C; Leheurteur M; Gouérant S; Petrau C; Théry JC; Picquenot JM; Veyret C; Frébourg T; Jardin F; Sarafan-Vasseur N; Di Fiore F
Oncotarget; 2016 Nov; 7(46):74448-74459. PubMed ID: 27801670
[TBL] [Abstract][Full Text] [Related]
39. Methylation status of the estrogen receptor 1 promoter predicts poor prognosis of acute-on-chronic hepatitis B liver failure.
Fan XP; Dou CY; Fan YC; Cao CJ; Zhao ZH; Wang K
Rev Esp Enferm Dig; 2017 Dec; 109(12):818-827. PubMed ID: 29082740
[TBL] [Abstract][Full Text] [Related]
40. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
